3 December 2015 - The National Institute for Health and Care Excellence is now recommending Novartis’ Farydak as a third-line treatment for patients with multiple myeloma after initially rejecting the drug for NHS use earlier this year.

For more details, go to: http://www.pharmatimes.com/Article/15-12-03/NICE_u-turn_on_Novartis_multiple_myeloma_drug.aspxhttp://www.pharmatimes.com/Article/15-12-03/NICE_u-turn_on_Novartis_multiple_myeloma_drug.aspx